Oppenheimer Reiterates a Buy Rating on Flexion Therapeutics (FLXN)
Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Flexion Therapeutics (FLXN) yesterday and set a price target of $19.00. The company’s shares closed last Tuesday at $13.06.
According to TipRanks.com, Brisebois is a 2-star analyst with an average return of 2.0% and a 35.8% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Kala Pharmaceuticals, and Aerie Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Flexion Therapeutics with a $21.75 average price target, which is a 70.6% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.98 and a one-year low of $5.01. Currently, Flexion Therapeutics has an average volume of 559.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.